Skip to main content

CCTG Connection


Published:
Category: Group updates
The 2023 CCTG Annual Spring Meeting of Participants

The CCTG Annual Spring Meeting of Participants will be held Friday, April 28 to Sunday, April 30 at the Chelsea Hotel, Toronto. As we close in on the meeting, we will continue to keep you updated on all of the deadlines, so stay tuned!

 

Read More
Published:
Category: News
Dr. Solar Vasconcelos awarded the Frances A Shepherd Award
Congratulations to Dr. Vasconcelos, a BC Cancer GI Medical Oncology Fellow, was selected by the CCTG review committee to be awarded the The Frances A Shepherd Award for his abstract: Transverse colon primary analysis for CO20 and CO17 which was selected for the ASCO Gastrointestinal Cancers Symposium. Read More
Published:
Category: Publications
Publications: MA33
CCTG MA33 primary publication: Radiation doses and fractionation schedules in non-low-risk ductal carcinoma in situ in the breast
 
Chua BH, Link EK, Kunkler IH, Whelan TJ, Westenberg AH, Gruber G, Bryant G, Ahern V, Purohit K, Graham PH, Akra M, McArdle O, O'Brien P, Harvey JA, Kirkove C, Maduro JH, Campbell ID, Delaney GP, Martin JD, Vu TT, Muanza TM, Neal A, Olivotto IA. Radiation doses and fractionation schedules in non-low-risk ductal carcinoma in situ in the breast (BIG 3-07/TROG 07.01): a randomised, factorial, multicentre, open-label, phase 3 study.
Read More
Published:
Category: Trials
Closed to Accrual: BL13 and substudy BL13 F
BL13 "A Randomized Phase II Trial Assessing Trimodality Therapy With or Without Adjuvant Durvalumab (MEDI4736) to Treat Patients with Muscle-Invasive Bladder Cancer and also the BL.13F sub-study " Electronic 'Real-Time' Patient Self-Reporting of Immunotherapy Symptomatic Adverse Events using the SYMPTOM-IQ Tool on the uMotif Mobile Health Application (APP): A Prospective Feasibility Sub-Study of BL13 [e-PRISM]" have both closed to accrual. Read More
Published:
Category: Trials
Trial closure: PR13 (MRC-PR10) RADICALS

PR13 (MRC-PR10) RADICALS: Radiotherapy and Androgen Deprivation In Combination After Local Surgery trial has been permanently closed.

RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Androgens can cause the growth of prostate cancer cells. Androgen deprivation therapy, such as goserelin, leuprolide, or bicalutamide, may lessen the amount of androgens made by the body. Giving radiation therapy together with androgen deprivation therapy may kill more prostate cancer cells.

Read More


Published:
Category: Group updates
Seeking CCTG Small Cell Lung Cancer (SCLC) Working Group Chair
The applicant should be a medical, radiation, surgical oncologist or pathologist, who has a research interest in SCLC, with leadership experience in clinical trials. The successful working group chair will work with the thoracic disease site leadership and executive to develop clinical trial proposals in SCLC, and be a champion of the working group to engage new and existing members to further its goals.
Read More
Published:
Category: Group updates
CCTG 2023-2024 New Investigator Cancer Trials Practicum
Applications are now open. This unique program and the first of its kind in Canada. It enables the best and brightest new Canadian oncology researchers to acquire training and experience in cancer clinical trial conduct. Read More
Published:
Category: Group updates
Frances Shepherd Award now accepting applications
CCTG is now accepting applications for the 2023 Frances Shepherd Award for any travel related to CCTG work (prior to travel and before the application deadline).
 
The Frances Shepherd Award is disbursed to one to two investigators or post-graduate trainees, traveling to present CCTG related work at major international meetings where the material has been accepted for presentation. Each award will be $1000.
Read More